Penumbra Inc (NYSE:PEN) EVP Robert D. Evans sold 40,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $89.89, for a total transaction of $3,595,600.00. Following the sale, the executive vice president now owns 11,704 shares of the company’s stock, valued at approximately $1,052,072.56. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Penumbra Inc (NYSE:PEN) traded down $5.95 during trading on Thursday, reaching $84.60. 1,104,347 shares of the company traded hands, compared to its average volume of 595,467. Penumbra Inc has a 12-month low of $64.85 and a 12-month high of $116.35. The firm has a market cap of $2,870.00 and a P/E ratio of 402.86.

Penumbra (NYSE:PEN) last posted its earnings results on Tuesday, November 7th. The company reported $0.01 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.06) by $0.07. Penumbra had a negative net margin of 2.19% and a negative return on equity of 1.95%. The firm had revenue of $83.90 million during the quarter, compared to the consensus estimate of $79.17 million. During the same quarter last year, the firm earned ($0.04) EPS. The firm’s revenue for the quarter was up 24.9% on a year-over-year basis. analysts predict that Penumbra Inc will post -0.15 EPS for the current year.

A number of institutional investors have recently bought and sold shares of PEN. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Penumbra by 10.9% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,159 shares of the company’s stock valued at $102,000 after purchasing an additional 114 shares during the last quarter. Verition Fund Management LLC acquired a new stake in Penumbra in the 2nd quarter valued at approximately $213,000. Teacher Retirement System of Texas purchased a new position in Penumbra in the 3rd quarter valued at approximately $214,000. Ameritas Investment Partners Inc. boosted its position in Penumbra by 10.8% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,573 shares of the company’s stock valued at $226,000 after buying an additional 250 shares during the period. Finally, Prudential Financial Inc. purchased a new position in Penumbra in the 2nd quarter valued at approximately $252,000. Hedge funds and other institutional investors own 71.71% of the company’s stock.

A number of brokerages have recently issued reports on PEN. BMO Capital Markets downgraded shares of Penumbra from an “outperform” rating to a “market perform” rating and cut their price target for the stock from $117.00 to $110.00 in a report on Tuesday, December 12th. They noted that the move was a valuation call. Canaccord Genuity raised their price target on shares of Penumbra from $100.00 to $113.00 and gave the stock a “buy” rating in a report on Wednesday, November 8th. Zacks Investment Research upgraded shares of Penumbra from a “sell” rating to a “hold” rating in a report on Wednesday, October 11th. Finally, JPMorgan Chase & Co. downgraded shares of Penumbra from an “overweight” rating to a “neutral” rating in a report on Tuesday. Four investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $111.50.

TRADEMARK VIOLATION WARNING: “Penumbra Inc (PEN) EVP Sells $3,595,600.00 in Stock” was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The legal version of this article can be read at https://www.americanbankingnews.com/2018/01/04/penumbra-inc-pen-evp-sells-3595600-00-in-stock.html.

About Penumbra

Penumbra, Inc is a healthcare company focused on interventional therapies. The Company designs, develops, manufactures and markets medical devices. It has a portfolio of products that addresses medical conditions and clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures.

Insider Buying and Selling by Quarter for Penumbra (NYSE:PEN)

Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.